ProCE Banner Activity

Elranatamab Monotherapy for R/R MM After Previous BCMA-Directed Therapy: Pooled Analysis of MagnetisMM Studies

Conference Coverage
Slideset

Elranatamab demonstrated activity for relapsed/refractory multiple myeloma following BCMA-directed ADC and CAR T-cell therapy in this pooled analysis of 4 MagnetisMM trials.

Released: June 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis